Eugia Pharma Receives USFDA Approval for Regadenoson Injection, 0.4 mg/5 mL (0.08 mg/mL) – Coming Soon
Published: October 26, 2022
Eugia US is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Regadenoson Injection, 0.4 mg/5 mL (0.08 mg/mL).
Indications for this product include:
Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress.